Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06833853 · ClinicalTrials.gov registry record
A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients
A clinical trial of Metastatic Breast Cancer (MBC), sponsored by Menarini Silicon Biosystems.
- Recruiting
- Registry status
- 187
- Enrollment target
- 1
- Study location
NCT06833853: Recruiting study of Metastatic Breast Cancer (MBC), sponsored by Menarini Silicon Biosystems.
NCT06833853 is a study of Metastatic Breast Cancer (MBC) that is actively recruiting participants, run by Menarini Silicon Biosystems. The registered enrollment target is 187 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06833853, a study of Metastatic Breast Cancer (MBC), is actively recruiting participants, sponsored by Menarini Silicon Biosystems.
- RECRUITING
- Registry status
- 187 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and expression of biomarkers Human Epidermal growth factor Receptor 2 (HER2), Estrogen Receptor (ER), and programmed death-ligand 1 (PD-L1) and cell free DNA/RNA (cfDNA/RNA) analysis.
Primary Outcome
The percentage of subjects for which the providers indicated positive impact on treatment decisions or response assessment of the cfDNA/RNA, CTC enumeration, and CTC expression assessments.CTC enumeration, CTC biomarker expression, and cfDNA/RNA results in subjects with MBC.
Conditions Studied
Study Locations (1)
Pennsylvania
- UPMC Magee Womens Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2026-03-13 |
| Est. Completion | 2028-10 |
What NCT06833853 shows while recruiting
NCT06833853 is an observational study that tracks outcomes without assigning an intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Metastatic Breast Cancer (MBC) appearing as the primary indexed condition, and to 0 interventions.
NCT06833853 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06833853 about?
NCT06833853 is a clinical study titled "A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients". The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and expression of biomarkers Human Epidermal growth factor Rece...
What is the current status of trial NCT06833853?
This trial is currently recruiting. The enrollment target is 187 participants. The study started on 2026-03-13. Estimated completion is 2028-10.
What conditions does trial NCT06833853 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer (MBC).
Who is sponsoring clinical trial NCT06833853?
This trial is sponsored by Menarini Silicon Biosystems, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06833853 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer (MBC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI